PHILADELPHIA –Researchers at the University of Pennsylvania School of Medicine have created the first animal model of age-related macular degeneration (AMD) caused by a mutation known to produce disease in people, an important first step in developing treatments. The study appears in the October issue of Human Molecular Genetics.
Drusen (extracellular deposits of protein and lipids that accumulate and can cause blindness) in macular degeneration.
A. Drawing of eye showing location of macula at the center of the retina.B. Photograph of the macula from a patient with drusen. C. Histologic section of retina showing drusen between the retinal pigment epithelium
Click on thumbnail
to view full-size image
Age-related macular degeneration is the most common cause of vision loss in elderly people, affecting more than 10 million people in the U.S. and about 50 million world-wide. Although it is a common and debilitating condition, prevention and treatment options are limited because AMD is a difficult condition to study.
“To better develop treatments for preventing the progression of AMD, we need to understand the real biochemical details of how AMD occurs,” says lead author Eric A. Pierce, MD, PhD, Associate Professor of Ophthalmology at Penn’s K.M Kirby Center for Molecular Ophthalmology. “To do that, we need a model, and now we have one.”
AMD is a difficult condition to investigate because it develops late in life - patients typically show symptoms of AMD after 60, and the only samples researchers could use for study were from people who died while they had the early stages of AMD, and at that point, the tissue is not useful to study the condition’s progression.
AMD is caused by the development of deposits between the retinal pigment epithelium and its basement membrane, called Bruch’s membrane. The material starts as basal deposits and becomes drusen, extracellular deposits of protein and lipids that accumulate and can cause blindness. In order to prevent the basal deposits from forming, researchers need to understand the mechanisms that cause them to form in the first place.
“By making this particular mutant mouse, we’ve made a model of early macular degeneration that’s caused by a mutation we know produces macular degeneration in people,” says Pierce. “We think it’s going to be a good model to study the pathogenesis of basal deposits.”
Some forms of macular degeneration are inherited, and one type is thought to be caused by a mutation in the Efemp1 gene. Pierce and colleagues created a mouse model of this inherited disorder by introducing the disease-causing mutation into the Efemp1 gene of mice. The resulting Efemp1-mutant mice develop the same basal deposits as people with AMD.
Pierce and colleagues plan to use the Efemp1-mutant mice to study how basal deposits form and what they are made of. The mice can also be used to test potential treatments to prevent basal deposit formation.
In addition to Pierce, Li Fu and Donita Garland of Penn; Zhenglin Yang, Erik Pearson and Kang Zhang of the University of Utah Health Sciences Center; Dhananjay Shukla and Anand Rajendran of the Aravind Eye Hospital & Postgraduate Institute of Ophthalmology; and Edwin M. Stone of the Howard Hughes Medical Institute are co-authors.
The Rosanne Silbermann Foundation, Research to Prevent Blindness, the Foundation Fighting Blindness, the F.M. Kirby Foundation, the Ruth and Milton Steinbach Fund, Ronald McDonald House Charities, the Macular Vision Research Foundation, the Howard Hughes Medical Institute and the National Eye Institute provided funding for this research.
PENN Medicine is
a $3.5 billion enterprise dedicated to the related missions
of medical education, biomedical research, and excellence in
patient care. PENN Medicine consists of the University of Pennsylvania
School of Medicine (founded in 1765 as the nation's first medical
school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #3 in the
nation in U.S.News & World Report's survey of top research-oriented
medical schools; and, according to most recent data from the
National Institutes of Health, received over $379 million in
NIH research funds in the 2006 fiscal year. Supporting 1,400
fulltime faculty and 700 students, the School of Medicine is
recognized worldwide for its superior education and training
of the next generation of physician-scientists and leaders
of academic medicine.
The University of Pennsylvania Health System includes
three hospitals — its flagship hospital,
the Hospital of the University of Pennsylvania, rated one of
the nation’s “Honor Roll” hospitals by U.S.News & World
Report; Pennsylvania Hospital, the nation's first hospital; and
Penn Presbyterian Medical Center — a
faculty practice plan; a primary-care provider network; two multispecialty
satellite facilities; and home care and hospice.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.